Ridogrel (R 68070) 是一种口服活性的血栓素 A2 合成酶 (combined thromboxane A2 synthetase) 抑制剂和血栓素 A2/前列腺素内过氧化物受体 (thromboxane A2/prostaglandin endoperoxide receptor) 阻滞剂。Ridogrel 是一种有效的抗血小板剂，具有抗炎活性。
货号:ajcx38252
CAS:110140-89-1
分子式:C18H17F3N2O3
分子量：366.33
溶解度:N/A
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Ridogrel (R 68070) is an orally active combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities[1][2][3].

In rats, R 68 070 (1.25 mg/kg orally, -2 h) singly prolongs tail bleeding times as much as a combination of TXA2 synthetase inhibition (dazoxiben 10 mg/kg) and TXA2/prostaglandin endoperoxide receptor blockade (BM 13177 40 mg/kg). In dogs, the compound reduces coronary thrombosis induced by electrical damage (1.25 mg/kg i.v.) and prevents the evolution of occlusion/reperfusion-induced arrhythmias into ventricular fibrillation (2.5 mg/kg i.v.)[2.

[1]. De Clerck F, et al. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo. Thromb Haemost. 1989;61(1):43-49.
[2]. Di Perri T, et al. Ridogrel, una nuova molecula antiaggregante piastrinica a doppio meccanismo d'azione. Profilo farmacologico e clinico [Ridogrel, a new platelet antiaggregant molecule with a double mechanism of action. A pharmacological and clinical profile]. Recenti Prog Med. 1991;82(10):533-540.
[3]. Carty E, et al. Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14(6):807-817.